Nintedanib in NSCLC: Evidence to date and place in therapy

Eugenio Fiorentino, Marta Castiglia, Francesco Passiglia, Antonio Russo, Viviana Bazan, Giuseppe Bronte, Nadia Barraco, Angela Listi', Antonio Galvano, Antonio Russo, Antonio Galvano, Marta Castiglia, Francesco Passiglia, Eugenio Fiorentino, Angela Listì, Nadia Barraco, Viviana Bazan, Sergio Rizzo, Giuseppe Bronte, Sergio Rizzo

Risultato della ricerca: Articlepeer review

16 Citazioni (Scopus)


The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and valuable oncogenes can receive standard chemotherapy as first-line treatment, with the possibility of adding bevacizumab. With regard to second-line treatment, nintedanib can improve the efficacy of docetaxel. Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors. The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. Therefore, the good results seen in the clinical trials with nintedanib in the second-line setting for NSCLC patients with adenocarcinoma subtype are encouraging enough to recommend it in clinical practice.
Lingua originaleEnglish
pagine (da-a)188-197
Numero di pagine10
RivistaTherapeutic Advances in Medical Oncology
Stato di pubblicazionePublished - 2016

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2730???


Entra nei temi di ricerca di 'Nintedanib in NSCLC: Evidence to date and place in therapy'. Insieme formano una fingerprint unica.

Cita questo